-
A Beacon of Hope: Cancer BiomarkersSharon and her daughter’s story underscores the potential of comprehensive genomic profiling to help inform cancer treatment decisions.
sponsored by Eli Lilly and Company
Researchers explore how the secret inhabitants of the digestive tract influence response to cancer treatment.
by Natalie Slivinski
-
CAR T-cell Therapy Prevents Progression in High-risk Smoldering MyelomaEarly study suggests an immunotherapy can eliminate precancerous cells in people with high-risk disease.
by Darlene Dobkowski -
Aromatase Inhibitor Use Linked to Blood Pressure, Diabetes RiskPeople who took aromatase inhibitors to prevent breast cancer recurrence for at least five years had a higher risk of developing cardiometabolic conditions.
by Eric Fitzsimmons -
Hypothyroidism Is Associated With Increased Survival in Some CancersSome cancer survivors develop hypothyroidism as a result of cancer treatment. Research shows this side effect is linked to prolonged survival in some cancer types.
by Darlene Dobkowski -
Targeted Therapy Prompts Responses in KRAS-mutated Lung CancerAn investigational targeted therapy controls cancer after previous KRAS inhibitor use.
by Eric Fitzsimmons -
Wearable Devices Help Monitor Patient Health After Cancer TreatmentResearchers evaluate whether devices that track health metrics like daily steps and heart rate can help predict clinical outcomes.
by Darlene Dobkowski
-
Cancer Risk Estimates: What Do Those Numbers Mean?An expert offers simplified explanations behind how cancer risk estimates like rate ratio, hazard ratio, relative risk, and absolute risk are calculated.
-
How to Treat Each Stage of Triple-negative Breast CancerA look at the current options for treating each stage triple-negative breast cancer and some of the potential advances to come.
Cancer Research at a Crossroads
The AACR Cancer Progress Report, which is published annually by the American Association for Cancer Research, tracks recent developments that impact cancer care. Click “Progress Report” below to find out more.
